Warner Chilcott bought for $5bn

Generic drug maker Actavis has agreed to acquire Dublin headquartered Warner Chilcott for about $5bn (€3.9bn) excluding net debt in a deal to expand in women’s health and urology.

Warner Chilcott investors will receive 0.16 shares of new Actavis stock for each Warner Chilcott share they own, Actavis said in a statement yesterday.

The agreement values each Warner Chilcott share at $20.08, a 4.5% premium over the stock’s closing price last Friday. Including Warner Chilcott’s more than $3bn in net debt, the total value of the acquisition is about $8.5bn.